BCM
Bayesian Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-25,700
| Closed | -$193K | – | 621 |
|
|
2024
Q4 | $193K | Buy |
+25,700
| New | +$193K | 0.02% | 572 |
|
|
2024
Q3 | – | Sell |
-43,200
| Closed | -$267K | – | 693 |
|
|
2024
Q2 | $267K | Buy |
+43,200
| New | +$267K | 0.03% | 535 |
|
|
2024
Q1 | – | Sell |
-60,600
| Closed | -$363K | – | 782 |
|
|
2023
Q4 | $363K | Sell |
60,600
-18,100
| -23% | -$108K | 0.04% | 454 |
|
|
2023
Q3 | $557K | Buy |
78,700
+63,700
| +425% | +$451K | 0.06% | 350 |
|
|
2023
Q2 | $106K | Buy |
+15,000
| New | +$106K | 0.01% | 689 |
|
|
2022
Q4 | – | Sell |
-40,454
| Closed | -$510K | – | 787 |
|
|
2022
Q3 | $510K | Buy |
+40,454
| New | +$510K | 0.1% | 277 |
|
|
2020
Q2 | – | Sell |
-27,100
| Closed | -$54K | – | 533 |
|
|
2020
Q1 | $54K | Buy |
+27,100
| New | +$54K | 0.01% | 721 |
|